2
Clinical Trials associated with Cetuximab biosimilar (EnZene Biosciences)A prospective, multicenter, Phase IV study to evaluate the safety and efficacy of biosimilar cetuximab either alone or in combination with investigator choice chemotherapy/ radiotherapy in patients with locoregionally advanced or recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN). - NIL
A prospective, multicenter, randomized, double blind, parallel group study to compare the efficacy and safety of biosimilar cetuximab versus innovator cetuximab in combination withplatinum-based chemotherapy in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN).
100 Clinical Results associated with Cetuximab biosimilar (EnZene Biosciences)
100 Translational Medicine associated with Cetuximab biosimilar (EnZene Biosciences)
100 Patents (Medical) associated with Cetuximab biosimilar (EnZene Biosciences)
100 Deals associated with Cetuximab biosimilar (EnZene Biosciences)